Key interactions (including with anticoagulants and antiepileptics) and contraindications are detailed in the relevant SmPCs (emc)
Studies reported that GLP1-RAs improve metabolic and reproductive parameters (such as menstrual regularity) in women with polycystic ovarian syndrome (PCOS), raising the possibility that GLP1-RAs may improve fertility in women with PCOS
Research published in early 2026 from Oxford confirms that weight regain after stopping GLP-1 medications happens faster than after behavioral weight loss programs alone roughly 0.7 pounds per month faster
In the same trial, 1-8% of patients reported injection site reactions with retatrutide, while no case was reported in the placebo group
GLP-1 medications, bariatric surgery, peptide therapy, and other medical weight loss treatments require evaluation by a licensed healthcare provider
So for me, itd be interesting to see what the time of resolution of these symptoms is. Kipnis said that research needs to prove to Medicare and insurance companies that obesity treatments should always be covered